盐酸格拉司琼结构式
|
常用名 | 盐酸格拉司琼 | 英文名 | Granisetron hydrochloride |
---|---|---|---|---|
CAS号 | 107007-99-8 | 分子量 | 348.870 | |
密度 | 1.33g/cm3 | 沸点 | 532ºC at 760mmHg | |
分子式 | C18H25ClN4O | 熔点 | 290-292°C | |
MSDS | 中文版 美版 | 闪点 | 275.6ºC | |
符号 |
GHS07 |
信号词 | Warning |
盐酸格拉司琼用途Granisetron(BRL 43694A)盐酸盐是5-HT3受体拮抗剂,可作为化疗后止吐剂。 |
中文名 | 盐酸格拉司琼 |
---|---|
英文名 | Granisetron hydrochloride |
中文别名 | 1-甲基-N-[内向-9-甲基-9-氮杂双环(3,3,1)壬烷-3-基]-lH-吲唑-3-甲酰胺盐酸盐 | N-(内-9-甲基-9-氮杂二环[3,3,1]壬-3-基)-吲哚-3-羧酰胺盐酸盐 | 1-甲基-N-[内向-9-甲基-9-氮杂双环[3.3.1]壬烷-3-基]-1H-吲唑-3-甲酰胺盐酸盐 | 格拉司琼盐酸盐 | 桥-N-(9-甲基-9-氯杂二环[3.3.1]壬-3-基)-1-甲基-1H-吲唑-3-羧酰胺盐酸盐 | 1-甲基-N-[(3-endo)-9-甲基-9-氮杂双环[3.3.1]壬-3-基]-1H-吲哚-3-甲酰胺盐酸盐 |
英文别名 | 更多 |
描述 | Granisetron(BRL 43694A)盐酸盐是5-HT3受体拮抗剂,可作为化疗后止吐剂。 |
---|---|
相关类别 | |
参考文献 |
密度 | 1.33g/cm3 |
---|---|
沸点 | 532ºC at 760mmHg |
熔点 | 290-292°C |
分子式 | C18H25ClN4O |
分子量 | 348.870 |
闪点 | 275.6ºC |
精确质量 | 348.171692 |
PSA | 50.16000 |
LogP | 3.44920 |
外观性状 | 白色至灰白色结晶固体 |
蒸汽压 | 0mmHg at 25°C |
折射率 | 1.69 |
储存条件 | Room temp |
更多 | 1.性状:白色或微黄白色结晶性粉末,无臭。 2.熔点(℃):290-292。 3.溶解度:易溶于水,较难溶于甲醇,极难溶于乙醇,几不溶于乙醚。 |
符号 |
GHS07 |
---|---|
信号词 | Warning |
危害声明 | H302 |
警示性声明 | P301 + P312 + P330 |
个人防护装备 | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
危害码 (欧洲) | Xn: Harmful;Xi: Irritant; |
风险声明 (欧洲) | R22 |
安全声明 (欧洲) | 26-36-37 |
危险品运输编码 | NONH for all modes of transport |
RTECS号 | NK7882200 |
海关编码 | 2933990090 |
~% 盐酸格拉司琼 107007-99-8 |
文献:US4886808 A1, ; |
~74% 盐酸格拉司琼 107007-99-8 |
文献:INKE, S.A. Patent: WO2008/151677 A1, 2008 ; Location in patent: Page/Page column 13 ; |
盐酸格拉司琼上游产品 3 | |
---|---|
盐酸格拉司琼下游产品 1 | |
化合物(I)和化合物(Ⅱ)反应,即得格拉司琼。用氯化氢-乙醇酸化,得到盐酸格拉司琼。
海关编码 | 2933990090 |
---|---|
中文概述 | 2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
申报要素 | 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期 |
Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Pronociceptive and Antinociceptive Effects of Buprenorphine in the Spinal Cord Dorsal Horn Cover a Dose Range of Four Orders of Magnitude.
J. Neurosci. 35 , 9580-94, (2015) Due to its distinct pharmacological profile and lower incidence of adverse events compared with other opioids, buprenorphine is considered a safe option for pain and substitution therapy. However, des... |
|
In vitro percutaneous absorption enhancement of granisetron by chemical penetration enhancers.
Drug Dev. Ind. Pharm. 39(4) , 561-8, (2013) Granisetron (GRN), a potent antiemetic agent, is frequently used to prevent nausea and vomiting induced by cancer cytotoxic chemotherapy and radiation therapy.As part of our efforts to further modify ... |
|
Comparison of the efficacy of ondansetron and granisetron to prevent postoperative nausea and vomiting after laparoscopic cholecystectomy: a systematic review and meta-analysis.
Surg. Laparosc. Endosc. Percutan. Tech. 23(1) , 79-87, (2013) Our purpose was to assess the prophylactic antiemetic effects of ondansetron versus granisetron for laparoscopic cholecystectomy.We searched Medline, Cochrane Central Register of Controlled Trials, Pu... |
Granisetron hydrochloride |
1-méthyl-N-[(3-endo)-9-méthyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide chlorhydrate |
1H-Indazole-3-carboxamide, 1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-, hydrochloride (1:1) |
1-Methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide hydrochloride (1:1) |
1H-indazole-3-carboxamide, 1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-, monohydrochloride |
MFCD01747034 |
Granisetron HCl |
1-Methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide hydrochloride |
1-Methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide |
1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide,hydrochloride |
1-Methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazol-3-carboxamidhydrochlorid |
Granisetron (Hydrochloride) |